Supernus Pharmaceuticals Inc (SUPN)
Return on assets (ROA)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Net income | US$ in thousands | -1 | 60,711 | 53,424 | 126,950 | 113,056 |
Total assets | US$ in thousands | 1 | 1,702,510 | 1,689,150 | 1,504,100 | 1,160,280 |
ROA | -100.00% | 3.57% | 3.16% | 8.44% | 9.74% |
December 31, 2023 calculation
ROA = Net income ÷ Total assets
= $-1K ÷ $1K
= -100.00%
Supernus Pharmaceuticals Inc's return on assets (ROA) has shown a declining trend over the past five years, dropping from 9.74% in 2019 to 0.10% in 2023. This indicates that the company's ability to generate profits from its assets has weakened significantly. The significant decrease in ROA may indicate operational inefficiencies, increased expenses, or a decrease in asset productivity. It is essential for the company to investigate the underlying reasons for the decline in ROA and implement strategies to improve asset utilization and profitability.
Peer comparison
Dec 31, 2023
Company name
Symbol
ROA
Supernus Pharmaceuticals Inc
SUPN
-100.00%
Abbott Laboratories
ABT
7.82%
AbbVie Inc
ABBV
3.61%
Alkermes Plc
ALKS
16.65%
Amphastar P
AMPH
9.09%
ANI Pharmaceuticals Inc
ANIP
2.08%
Arcus Biosciences Inc
RCUS
-28.04%
Biomarin Pharmaceutical Inc
BMRN
2.45%
Bristol-Myers Squibb Company
BMY
8.43%
Catalent Inc
CTLT
-10.69%
Catalyst Pharmaceuticals Inc
CPRX
15.19%